Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.46 |
| ▸ | NOS2 | P35228 | 13/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504032 | 0.96 | NOS2 (0.40) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL7693316 | 0.96 | NOS2 (0.40) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| Oxalic Acid SCHEMBL6491863 | 0.89 | SLC6A4 (0.59) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6492890 | 0.88 | NOS2 (0.40) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| Oxalic Acid SCHEMBL6488920 | 0.85 | SLC6A2 (0.46) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL7680237 | 0.85 | SLC6A4 (0.54) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6491310 | 0.85 | SLC6A4 (0.54) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6504623 | 0.80 | SLC6A2 (0.40) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL7174582 | 0.80 | SLC6A2 (0.40) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| Oxalic Acid SCHEMBL6500140 | 0.79 | NOS2 (0.58) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887871-B2 | Use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | NOS1, XDH, NOS2 | SLC6A4 2468/4885NOS2 3/4885CYP2D6 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.